Largest Personal CGM Study Ever Conducted. Published in the New England Journal of Medicine!

Medtronic Diabetes applauds the Juvenile Diabetes Research Foundation (JDRF) for funding the largest clinical trial to ever demonstrate the value Personal CGM (real-time continuous glucose monitoring). The study compares Personal CGM (with supplemental meter readings) to standard meter readings over a 6-month period. And… the results are in!

Study Validates

• The study validates what we already know—people who use Personal CGM can substantially improve their blood sugar control

More Usage = Better Control

• Patients who use Personal CGM the most experience the most benefits
• In fact, patients 25 years and older had the most device usage, and they experienced a statistically significant A1C reduction of .53%
• All patients, regardless of their age, experienced A1C reductions when they used the device more than six days a week
• All patients, regardless of their age, experienced A1C reductions when they used the device at least six days a week

Less Fear of Hypoglycemia

• The study showed that A1C improvements occurred without an increase in hypoglycemia

Growing Body of Evidence

• This study builds upon the growing body of evidence for personal CGM
• We applaud the JDRF for funding studies that will assist us in improving reimbursement for patients. In fact, the payor community already sees the value of this therapy, as evidenced by the fact so many major payors have already developed policies for personal CGM coverage.

Medtronic Diabetes is the world leader in Personal CGM therapy. We offer the world's only integrated system that combines personal CGM with insulin pump therapy in the MiniMed Paradigm^® REAL-Time System. We also offer the most robust stand-alone Personal CGM device—the Guardian^® REAL-Time System.

Learn more about the most advanced technology available